H3B-6527 clinical biomarker assay development and characterization of HCC patient samples.

Pavan Kumar,Vicki Rimkunas,Kun Yu,Zhaojie Zhang,Crystal Mackenzie,Joanne Schindler,Peter C. Smith,Ping Zhu,Anand Selvaraj,Lihua Yu,Subhasree Das,Jaya Julie Joshi

H3B-6527 clinical biomarker assay development and characterization of HCC patient samples.

2019

Pavan Kumar
Vicki Rimkunas
Kun Yu
Zhaojie Zhang
Crystal Mackenzie
Joanne Schindler
Peter C. Smith
Ping Zhu
Anand Selvaraj
Lihua Yu
Subhasree Das
Jaya Julie Joshi

4121Background: FGFR4/FGF19 signaling axis is a novel therapeutic target in HCC. Multiple covalent FGFR4 inhibitors, including H3B-6527, are under clinical development. Preclinical efficacy studies...

Keywords:

Pathology
Biomarker (medicine)
Medicine
clinical biomarker
Internal medicine
Oncology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations